USPTO 2015–2025 USPTO PatentsView US Corporation

IGM Biosciences, Inc.

USPTO PatentsView assignee record - 20 granted patents across 6 technology areas, recorded in grant years 2016–2023. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07K (PEPTIDES).

The verdict

According to USPTO PatentsView, IGM ranks #14,679 of 50,000 tracked US assignees by granted-patent volume, with 20 patents across 6 technology areas.

#14,679
of 50,000 US assignees by volume
Top 46%
by Innovation Score (36.4/100)
23.1
avg claims per patent
+300%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R14679 · US Corporation #14,679 · 20 grants

GRANTS-SMALL · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-DENSE · TYPE-USCORP · VEL-SURGE · BOOK-FULL

  • GRANTS-SMALL 20 grants
  • MID-PACK #14,679/50,000
  • PHOTO-FINISH Horizon Therapeutics
  • CPC-NARROW C07K · 6 areas
  • INNOV-THIN 36.4/100
  • CLAIMS-DENSE 23.1 claims/avg
  • TYPE-USCORP US Corporation
  • VEL-SURGE +300% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: Horizon Therapeutics, Llc (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Innovation-score neighbourhood around IGM

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows IGM Biosciences, Inc. stamps GRANTS-SMALL, MID-PACK, PHOTO-FINISH, CPC-NARROW, INNOV-THIN, CLAIMS-DENSE, TYPE-USCORP, VEL-SURGE, BOOK-FULL. Volume places it #14,679 of 50,000; Innovation Score 36.4/100 sits in the top 46% of the PatentsView-derived corpus. Closest grant-volume peer on this plate is Horizon Therapeutics, Llc (±0 grants).

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Portfolio overview

IGM Biosciences, Inc. has been granted 20 US utility patents between 2016 and 2023, placing IGM Biosciences, Inc. at #14,679 of 50,000 across all assignees tracked by PlainPatent. This portfolio spans 6 distinct Cooperative Patent Classification (CPC) subclasses, averaging 23.1 claims per patent with primary concentration in C07K (PEPTIDES). As a US Corporation, IGM Biosciences, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, IGM sits between Horizon Therapeutics, Llc (20 patents, rank #14,670) and Inait Sa (20 patents, rank #14,678) - the closest US assignees by grant volume. The composite Innovation Score of 36.4/100 blends portfolio volume, grant velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Grant cadence records the difference between two grant-year windows. Between 2020 and 2024 the company received 16 grants, compared with 4 in the 2015–2019 window, a +300% shift in five-year grant velocity. Both windows cover five complete grant years; the latest PatentsView year is a partial release and is excluded from this comparison, though it still appears in the yearly table and chart below. Grant timing can lag the related application by years, so this comparison does not establish current R&D spending, strategic intent, or a company’s application activity. The US Corporation classification provides context for the assignee record, not a conclusion about its business strategy.

Claim depth and technology breadth describe this aggregate record. IGM Biosciences, Inc.'s 23.1 average claims per patent is an average count, not a measure of claim scope, legal strength, enforceability, or design-around risk. The record spans 6 CPC subclasses. Combined with portfolio volume, these figures let readers compare the documented grant records of assignees in similar technology classes.

Who files at IGM's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows IGM holds 20 patents at rank #14,674, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near IGM

By rank, the assignees closest to #14,674 in granted patent volume.

Leaders in C07K (Peptides)

Other assignees with the most granted patents in IGM's primary technology class.

IGM's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

36 Top 46% higher than 54% of 50,000 US assignees

0–10: 687 US assignees (1%). Below this entry. 10–20: 2,527 US assignees (5%). Below this entry. 20–30: 13,162 US assignees (26%). Below this entry. 30–40: 15,294 US assignees (31%). This entry sits in this band. 40–50: 11,491 US assignees (23%). Above this entry. 50–60: 5,058 US assignees (10%). Above this entry. 60–70: 1,537 US assignees (3%). Above this entry. 70–80: 234 US assignees (0%). Above this entry. 80–90: 10 US assignees (0%). Above this entry. 90–100: 0 US assignees (0%). Above this entry. This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

1234567 201620192020202120222023 4
USPTO utility patent grants by year · 2016–2023

Grants by year

Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.

View data table
IGM Biosciences, Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2016 2 10.0%
2019 2 10.0%
2020 6 30.0%
2021 4 20.0%
2022 2 10.0%
2023 4 20.0%

Where it ranks

Overall rank by patents

#14,679

of 50,000 tracked assignees

Innovation Score

36.4 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.